Literature DB >> 10835633

Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency.

I Netchine1, M L Sobrier, H Krude, D Schnabel, M Maghnie, E Marcos, B Duriez, V Cacheux, A v Moers, M Goossens, A Grüters, S Amselem.   

Abstract

Combined pituitary hormone deficiency (CPHD) has been linked with rare abnormalities in genes encoding transcription factors necessary for pituitary development. We have isolated LHX3, a gene involved in a new syndrome, using a candidate-gene approach developed on the basis of documented pituitary abnormalities of a recessive lethal mutation in mice generated by targeted disruption of Lhx3 (ref. 2). LHX3, encoding a member of the LIM class of homeodomain proteins, consists of at least six exons located at 9q34. We identified a homozygous LHX3 defect in patients of two unrelated consanguineous families displaying a complete deficit in all but one (adrenocorticotropin) anterior pituitary hormone and a rigid cervical spine leading to limited head rotation. Two of these patients also displayed a severe pituitary hypoplasia, whereas one patient presented secondarily with an enlarged anterior pituitary. These LHX3 mutations consist of a missense mutation (Y116C) in the LIM2 domain at a phylogenetically conserved residue and an intragenic deletion predicting a severely truncated protein lacking the entire homeodomain. These data are consistent with function of LHX3 in the proper development of all anterior pituitary cell types, except corticotropes, and extrapituitary structures.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10835633     DOI: 10.1038/76041

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  59 in total

1.  Molecular evolution of the homeodomain family of transcription factors.

Authors:  S Banerjee-Basu; A D Baxevanis
Journal:  Nucleic Acids Res       Date:  2001-08-01       Impact factor: 16.971

Review 2.  Other transcription factors and hypopituitarism.

Authors:  Laurie E Cohen; Sally Radovick
Journal:  Rev Endocr Metab Disord       Date:  2002-12       Impact factor: 6.514

3.  Lhx3 is required to maintain cancer cell development of high-grade oligodendroglioma.

Authors:  Hongliang Liu; Wei Liu; Bin Zhu; Qiang Xu; Xiaowei Ni; Ji Yu
Journal:  Mol Cell Biochem       Date:  2014-11-16       Impact factor: 3.396

4.  Molecular and evolutionary analysis of the growth-controlling region on the human Y chromosome.

Authors:  Stefan Kirsch; Birgit Weiss; Klaus Zumbach; Gudrun Rappold
Journal:  Hum Genet       Date:  2003-10-25       Impact factor: 4.132

Review 5.  From panhypopituitarism to combined pituitary deficiencies: do we need the anterior pituitary?

Authors:  Catherine Carrière; Anatoli Gleiberman; Chijen R Lin; Michael G Rosenfeld
Journal:  Rev Endocr Metab Disord       Date:  2004-03       Impact factor: 6.514

6.  Critical Roles of the LIM Domains of Lhx3 in Recruiting Coactivators to the Motor Neuron-Specifying Isl1-Lhx3 Complex.

Authors:  So Yeon Seo; Bora Lee; Seunghee Lee
Journal:  Mol Cell Biol       Date:  2015-08-10       Impact factor: 4.272

7.  A recessive mutation resulting in a disabling amino acid substitution (T194R) in the LHX3 homeodomain causes combined pituitary hormone deficiency.

Authors:  Susanne Bechtold-Dalla Pozza; Stefan Hiedl; Julia Roeb; Peter Lohse; Raleigh E Malik; Soyoung Park; Mario Durán-Prado; Simon J Rhodes
Journal:  Horm Res Paediatr       Date:  2012-01-26       Impact factor: 2.852

Review 8.  Pituitary stem cell update and potential implications for treating hypopituitarism.

Authors:  Frederic Castinetti; Shannon W Davis; Thierry Brue; Sally A Camper
Journal:  Endocr Rev       Date:  2011-04-14       Impact factor: 19.871

9.  Three novel single-nucleotide polymorphisms of the bovine LHX3 gene.

Authors:  Y J Jing; X Y Lan; H Chen; L Z Zhang; C L Zhang; C Y Pan; M J Li; G Ren; T B Wei; M Zhao
Journal:  J Biosci       Date:  2008-12       Impact factor: 1.826

Review 10.  Growth hormone - past, present and future.

Authors:  Michael B Ranke; Jan M Wit
Journal:  Nat Rev Endocrinol       Date:  2018-03-16       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.